Introduction
HIV-1 requires RT to copy its single-stranded RNA genome into a double-stranded DNA copy for integration into the host genome. To date, the cornerstones of successful HIV treatment are NRTIs. The lack of a 3′-hydroxyl group causes phosphorylated NRTIs to chain-terminate viral reverse transcripts. However, treatment with NRTIs is limited by their toxicity to the host. Dose limiting adverse effects sometimes arise from interactions with mitochondrial DNA polymerase γ (Parker & Cheng, 1994; Johnson et al., 2001 ) and other cellular polymerases (Kukhanova et al., 1995) . Resistance also commonly occurs due to the rapid replication of HIV and the constant selection of mutant virus with reduced NRTI sensitivity (Larder, 1994; Coffin, 1995) . These facts illustrate the need for new compounds with different metabolic, toxicity and resistance profiles in order to increase the duration of effective HIV treatment. This review focuses on incorporation of fluorinated and unfluorinated dCMP analogues by HIV-1 RT with the goal of giving valuable insights to be applied in the rational design of new agents more effective at combating viral infection.
Mechanistic insight from a transient kinetic approach
Steady-state kinetic analyses, where primer/template is in large excess over enzyme, can provide useful information concerning the overall affinity and incorporation efficiency for the interaction of HIV-1 RT with nucleotide substrates or analogues. However, a steady-state approach is unable to elucidate detailed interactions of nucleotides with RT at the polymerase active site (Kati et al., 1992; Furman et al., 2000) due to the inability of this type of analysis to resolve kinetic steps masked by the overall rate-limiting step of a reaction. This is a particularly salient point when considering the ordered mechanism of single nucleotide incorporation by RT that is similar to a number of other polymerases ( Figure 1 ). In this scheme the overall rate-limiting step follows nucleotide incorporation and reflects the dissociation of the elongated primer/template product from the enzyme (k ss ). Determination of the kinetic parameter for this step does not provide detailed quantitative information or insight toward understanding how a nucleotide substrate or analogue interacts with the polymerase active site during incorporation. Rather, substrate recognition during single nucleotide incorporation is best reflected by the rate-limiting step for chemical catalysis (k pol ). This step is thought to involve a conformational change in the enzyme just prior to incorporation (indicated by an asterisk in Figure  1 ). The k pol can only be directly measured by examining chemical catalysis under conditions in which enzyme is used in quantities near stoichiometric equivalence with primer/template and the rates of nucleotide incorporation using transient kinetic methodology are measured (for general transient kinetic review, see Johnson, 1992) .
In the comparative studies discussed in this review, kinetic parameters for the natural substrate (dCMP) and its analogues' incorporation by HIV-1 RT are examined (Figure 2 ). Methods used for the generation of new data AS Ray et al. 116 ©2003 International Medical Press Figure 1 . Mechanism of single nucleotide incorp-oration by HIV-1 RT are similar to those described in reports discussed in this review (Feng & Anderson, 1999a; Feng & Anderson, 1999b; Feng et al., 1999; Ray et al., 2002a 
Fluorine in drug design
Fluorine substitution can serve to impart favourable properties to inhibitory agents (Welch, 1987; Pankiewicz, 2000) . Fluorine can often be used to replace a hydroxyl group because it is isosteric with oxygen (Bondi, 1964) and has a similar polarity and the ability to be a weak hydrogen bond acceptor (Howard et al., 1996) . Fluorine can also serve as a replacement for hydrogen on a methylene unit without causing a large steric perturbation due to its compact size. This type of substitution gives the potential of endowing novel electrostatic interactions to the modified compound. Due to these properties, fluorine substitution has been observed to be effective at modulating the activity of many anti-HIV and -HBV nucleoside analogues (Herdewijn et al., 1987; Schinazi et al., 1992b; Lin et al., 1994; Lin et al., 1996; Chen et al., 1998; Chu et al., 1998; Dutschman et al., 1998; Lee et al., 1999; Shi et al., 1999; Lee et al., 2002 Ray et al., 2002a; c Feng & Anderson, 1999a; d Feng et al., 1999;  e bold and underlined represents a significant improvement in the kinetic parameter as a result of 5-fluorine; f bold represents a statistically significant worse kinetic change as a result of 5-fluorine. Table 1 . Effects of flurorine on cytidine analogue incorporation into a DNA 23-mer primer directed by a DNA or RNA 45-mer template 2′-or 3′-position of the deoxyribose ring in order to either mimic the presence of a 3′-hydroxyl or to stabilize the nucleoside (Herdewijn et al., 1987; Lee et al., 1999; Lee et al., 2002) . Modifying the 5-or 2′-position with a fluorine can reduce toxicity (Schinazi et al., 1992b; Tsai et al., 1994) and increase antiviral potency (Schinazi et al., 1992b; Lin et al., 1994; Lin et al., 1996; Lee et al., 1999) .
Kinetic consequences of 5-and 2′-fluorine addition on HIV-1 RT incorporation of β-D-2′−deoxycytidine (dC) analogues
Fluorine alters one or more of the three kinetic parameters defined for DNA-or RNA-directed nucleotide analogue incorporation by HIV-1 RT (Table 1 ). These data suggest that interactions with the RT active site are affected. While maximum rates of incorporation (k pol ) for D-5-fluorinated nucleotides generally vary by less than twofold compared to their unfluorinated counterparts, D-D4FCMP is a notable exception as it is incorporated 5.9-fold faster during DNA-directed synthesis than D-D4CMP (Figure 3, panel A) . Accordingly, the combined consequences of these changes in kpol and Kd cause all D-5-fluorinated dCTP analogues to be approximately threefold more efficiently incorporated (k pol /K d ) during DNAdirected incorporation. In contrast, during RNA-directed incorporation D-D4FCTP is the only nucleotide more efficiently incorporated (2.8-fold) than its unfluorinated counterpart and D-ddFCTP is the only 5-fluorinated Dor L-analogue noted to be less efficiently incorporated (3.9-fold) than its unfluorinated counterpart. D-D4FCTP is unique, being the only D-analogue to be a better substrate during both DNA-and RNA-directed incorporation AS Ray et al. 118 ©2003 International Medical Press than its unfluorinated counterpart. D-D4FC (Reverset TM , Pharmasset, Inc.) is currently in phase II clinical trials for HIV (Murphy et al., 2002 , Antiviral Research HIV DART 2002 Schinazi et al., 2002a) .
Interestingly, D-D4CTP is found to be a surprisingly poor substrate for HIV-1 RT. Its efficiency of incorporation is six-and 9.6-fold less than dCTP during DNA-and RNA-directed incorporation, respectively (Table 1) . This is in contrast to D-D4TTP and D-D4GTP which are effective at mimicking their corresponding natural nucleotides (Vaccaro et al., 1999; Ray et al., 2002b) . These results suggest that there may be base specific interactions important in nucleotide analogue incorporation. There is precedence to believe this to be the case in light of kinetic and structural studies on the large fragment of DNA polymerase I from Thermus aquaticus (Klentaq 1). These studies show that ddGTP is an order of magnitude better substrate than the other 2′,3′-dideoxynucleotides due to specific interactions in the Klentaq 1 active site (Li & Waksman, 2001 ). The efficiency of incorporation of D-D4CTP by HIV-1 RT is enhanced by the addition of a 5-fluorine, as D-D4FCTP is an excellent substrate relative to dCTP. This result may suggest that important interactions occur with the base in a region near the 5-position of the pyrimidine ring (discussed further below).
In contrast to D-isomers, which show the most prominent changes in binding, 5-fluorination caused a consistent two-to threefold increase in the k pol values for L-isomers during both DNA-and RNA-directed incorporation (Table 1, Figure 3, panel B) . While both L-FTCTP and LddFCTP show improved binding with one of the primer/templates tested with respect to their unfluorinated counterparts, L-D4FCTP binds two-to fourfold weaker than L-D4CTP during DNA-and RNA-directed incorporation, respectively. For reasons including high antiviral potency, not reflected in its interaction with HIV-1 RT in these kinetic assays, L-D4FC (elvucitabine, Achillion Pharmaceuticals, Inc.) is currently being developed as an anti-HIV and -HBV agent (Dunkle et al., 2002) .
L-FTCTP is a 2.5-fold better substrate during DNAdirected synthesis and a ninefold superior substrate during RNA-directed synthesis than 3TCTP (L-BCH-189TP, Table 1 ). The ninefold enhancement in incorporation efficiency during RNA-directed L-FTCMP incorporation is the largest change in response to the addition of a 5-fluorine noted to date. This is suggested to be, at least in part, responsible for L-FTC's increased activity over 3TC in anti-HIV potency in vitro (Table 3) (Schinazi et al., 1992b; Faraj et al., 1994; Feng et al., 1999 (Otto et al., 2002, Antiviral Research HIV DART 2002 Final Program and Abstract Book, Abstract 51) .
In contrast to the rarely negative effect of a 5-fluorine substitution, the 2′-fluorine substitution of D-D4FCTP (to make D-2′-F-D4FCTP) causes a 14-and 5.9-fold decrease in the efficiency of incorporation during DNAand RNA-directed synthesis, respectively (Table 1; Figure  3 , panel A). The decreased efficiency reflects a 6.3-to 2.3-fold decrease in k pol and a 2.1-and 2.6-fold increase in K d during DNA-and RNA-directed incorporation, respectively. These results suggest that the 2′-fluorine substitution of this analogue binds in an unfavourable manner in the RT active site (discussed further below).
Structural implications for the kinetic data
The kinetic changes for the incorporation of enantiomers of dCMP analogues in response to 5-fluorination may be attributable to an interaction with arginine 72 in the RT active site. Arg 72 is the only amino acid within 5 Å of the anticipated position of the 5-fluorine [similar to the position of the methyl unit of thymidine in the crystal structure of RT bound to TTP and primer/template (Figure 4 ) (Huang et al., 1998) ]. In addition to its role in contacting the alpha phosphate, interactions with the base may be facilitated by the presence of three nitrogens capable of forming hydrogen bonds. Fluorine's ability to be a hydrogen bond acceptor may allow for it to interact with Arg 72 placing L-isomers in a more favourable position for catalysis and giving D-isomers another favourable contact within the RT active site. These interactions potentially explain the observation of increased rates of incorporation and binding affinities for L-and D-isomers, respectively. The kinetic changes observed for nucleotide analogues in this study may belie an important role for this residue in substrate recognition by HIV-1 RT. Contacts with both the base and α phosphate may make Arg 72 sensitive to slight alterations in nucleotide structure occurring as a result of modifications. Gln 151 may also play a role in recognition of 5-fluorocytidine nucleotides, as a recent crystal structure of RT bound to an AZTMP chain-terminated primer/template shows a hydrogen bond between Gln 151 and the base of AZTMP (Sarafianos et al., 2002) .
The 2′-fluorine is positioned in a similar location to the 2′-hydroxyl of an RNA nucleotide. Tyr 115 is known to exclude the binding of RNA nucleotides by sterically disallowing the presence of a 2′-hydroxyl, leading it to be referred to as the steric gate of RT (Ding et al., 1998; Boyer et al., 2000) . A similarly positioned residue in other polymerases is considered to have the same function ( Joyce, 1997; Astatke et al., 1998) . The poor incorporation of D-2′-F-D4FCMP and the small atomic radius of fluorine may suggest that Tyr 115 and perhaps the carbonyl of Gln 151 also serve as an electrostatic gate limiting the incorporation of nucleotides with polar 2′-substitutions. However, the previously noted increase in stability imparted to nucleoside analogues by 2′-substitutions (Watanabe et al., 1983; Marquez et al., 1990 ) may outweigh the negative effects on incorporation. Molecular dynamics simulations also suggest the presence of a 2′-fluorine may perturb the hydrogen bond between Arg 72 and the α phosphate perhaps disturbing the triphosphate binding pocket (Y Chong and CK Chu, University of Georgia, unpublished findings).
Initial results on D-and L-BCH-189MP incorporation suggest that RT has a low enantiomeric selectivity (Feng & Anderson, 1999a ). 3TC's (L-BCH-189) low toxicity in cell culture and poor incorporation of 3TCMP by human DNA polymerases may have led to the belief that human enzymes are more enantiomerically selective than RT. Recent results have shown this not to be the case for RT, where enantiomeric selectivity appears to be largely dependent on specific ribose ring modifications. It is found that, unlike the oxathiolane nucleotides (BCH-189TP and FTCTP), RT has relatively high enantiomeric selectivity for D4CTP (Ray et al., 2002a) and ddCTP in unfluorinated and 5-fluorinated forms (Table 1) . No general trend has been found with human DNA polymerases either. In fact, the L-isomer of dioxalanecytidine triphosphate (LOddCTP) is actually a better inhibitor than its enantiomeric AS Ray et al. 120 ©2003 International Medical Press Ray et al., 2002a. Image generated from the crystal structure of the ternary complex of HIV-1 RT, primer/template and TTP (Huang et al., 1998) partner for some human DNA polymerases (Kukhanova et al., 1995; Grove & Cheng, 1996) and L-OddC (Troxatyl TM , Shire Pharmaceuticals Plc.) is currently being developed as an anticancer agent (Schwartz et al., 1998) .
Certain modifications may have differential effects depending on the enantiomer. For example, the sulphur in the oxathiolane nucleotides causes the D-isomers of these nucleotides to be very poor substrates, while the L-isomers have improved incorporation. L-FTCMP is one of the best incorporated L-isomers and its efficiency of incorporation is markedly improved over L-ddFCMP where a carbon occupies the 3′-position. Similarly, while the 2′-fluorine was found to have a negative effect on the incorporation of the D-isomer of D4FCMP, the cellular antiviral activity of the L-isomer is not affected by this modification (Lee et al., 1999) . Both of these findings illustrate the large difference in steric and electrostatic constraints for the 2′-and 3′-positions in the D-versus L-conformation. These differences are apparent in structural models of L-analogues binding in the HIV-1 RT active site (Feng & Anderson, 1999a; Gao et al., 2000; Ray et al., 2002a) . However, as discussed below, the steric contact with the 2′-and 3′-position of L-isomers may be increased by the M184V mutation causing marked changes in incorporation kinetics and antiviral activity (Tables 2 and 3) .
In general, a number of studies with HIV-1 RT have noted that the efficiency is higher for RNA-directed versus DNA-directed incorporation although the molecular mechanism has remained elusive (Kerr & Anderson, 1997; Vaccaro et al., 1999; Ray et al., 2002b ). An unpublished crystal structure of RT bound to TTP and a DNA/RNA primer/template offers no further clues, as the distances between many important amino acids and TTP remain unchanged (SC Harrison, Harvard University, Mass., USA, personal communication). D-D4FCTP and L-FTCTP were the only two nucleotide analogues to show a consistent increase in their efficiency of incorporation during both DNA-and RNA-directed synthesis in response to the addition of a 5-fluorine substitution, perhaps illustrating their effectiveness during multiple stages of viral replication.
Incorporation of dCMP analogues by RT

M184V
In vitro and in vivo studies show that the M184V mutation selected for by treatment with 3TC causes a 500-to 1000-fold decrease in 3TC's anti-HIV activity Boucher et al., 1993; Tisdale et al., 1993; Schuurman et al., 1995) . A combination of kinetic studies and structural modeling have led to the hypothesis that 3TC resistance is caused by the addition of a β-branched amino acid at position 184, causing steric hindrance towards the binding of 3TCTP (Feng & Anderson, 1999b; Sarafianos et al., 1999; Gao et al., 2000) . A recent transient kinetic report also shows that L-D4FCMP incorporation is selected against by the M184V/I mutation while D-D4FCTP is unaffected (Table  2) (Ray et al., 2002a) . Here we report that L-ddFCTP is used approximately 100-fold less efficiently by RT M184V than RT WT (Table 2) . Taken together these results suggest that high-level resistance conferred by the M184V mutation may be a general problem for all NRTIs with an 'unnatural' Schinazi et al., 1994; j Schinazi et al., 1992b; k Schinazi et al., 1993; Anti-HIV activity determined against xxBRU. Pitt. virus in PBM cells;
x anti-HIV activity determined against LAI strain in PBM cells; y anti-HIV activity determined against HXB2 strain in MT-4 cells; z anti-HIV activity determined against HIV-IIIB in MT-2 cells. NRTIs usually at least 10-fold less effective in this particular MT-2 assay.
L-ribose ring conformation (Schinazi et al., 2001b) . Some Disomers are also affected by the M184V mutation, although to a lesser extent (Schinazi et al., 2001a) (Table 3) . The large distances between D-analogues and β-branched amino acids at position 184 make it unlikely that steric hindrance plays a role in this resistance. Recent work suggests the M184V mutation causes a change in positioning of other active site residues including Tyr 115 and alterations in the substrate selectivity of HIV-1 RT (Ray et al., 2002a; Ray et al., 2002b) .
Relationship to biological findings
D-D4FCMP and L-FTCMP′s improved incorporation into the two primer/template combinations most encountered by HIV-1 RT may in-part explain the effectiveness of their corresponding nucleoside analogues, D-D4FC (Reverset) and L-FTC (emtricitabine), against HIV and progression into clinical trials. However, the order of magnitude increase in antiviral activity in cell culture for L-D4FC (elvucitabine) and L-ddFC over their unfluorinated counterparts, or the increased antiviral activity of L-analogues over their D-enantiomeric partners are not explained by the kinetic data (Table 3 ). These data suggest that other factors such as transport, activation and other metabolic processes and cytototoxicity must be involved in defining antiviral potency. Studies on the effects of fluorination and enantiomeric form on other enzymes important for nucleoside activity, such as cytidine deaminases (Chang et al., 1992) , kinases (Arner et al., 1992; Shewach et al., 1993; Krishman et al., 2002) and exonucleases (Chou et al., 2000; Chou & Cheng, 2002) , could further elucidate the pharmacological basis for the differences in cellular activity of these nucleosides.
The kinetic changes observed in response to fluorination indicate differences in the binding of analogues to RT that may have important implications for drug resistance. In a recent report it was found that the M184V mutation imparts low-level resistance to D-2′-F-D4FC (Lee et al., 2002) . This result is surprising because neither in kinetic (Table 2) (Ray et al., 2002a; Schinazi et al., 2002a) nor cell-based assays Geleziunas et al., 2003) has the M184V mutation shown any resistance to D-D4FC suggesting that the 2′-fluorine causes an altered resistance profile. Further elucidation of the resistance profiles of these NRTIs may reveal more surprising results and novel insights into the mechanisms of resistance for mutations affecting antiviral therapy.
Future perspectives
The triphosphates of L-FTC and D-D4FC were the only nucleotide analogues that showed consistently improved kinetic behavior as a result of fluorine addition at the 5-position. However, the relatively small and rarely negative effects of fluorine at the 5-position may indicate that it can be used to alter interactions with other enzymes without sacrificing nucleotide analogue incorporation by HIV-1 RT. Interactions with other cellular factors are likely responsible for the increased antiviral potency of some 5-fluorinated analogues, including L-D4FC, despite no improvement in RT incorporation. Although the 2′-fluorine substitution caused a negative effect on incorporation at the level of both the k pol and K d by RT WT , the advantage of increased chemical stability and other undefined biological changes may overshadow these short comings.
Previously identified nucleosides should be re-examined for their potential in antiviral therapy in light of new information on the impact of fluorination and the potential to modulate their activity. One example of this is the promising rediscovered activity of dioxolanecytidine against HIV. Both the D-and L-isomers of dioxolanecytidine were previously discovered to have potent antiviral activity and toxicity in cell culture (Kim et al., 1992; Kim et al., 1993; Grove et al., 1995) . As discussed above, the L-analogue's (L-OddC) high toxicity, perhaps due to its surprisingly effective incorporation by human polymerases, has led to its development as a promising anticancer agent. Reassessment of the D-isomer has recently found it to have some promising antiviral characteristics . With previously discovered NRTIs being re-examined in a new mechanistic light and new compounds including 2′-substituted (Carroll et al., 2003) and base-modified (Stuyver et al., 2003) cytidine analogues effective against the hepatitis C virus the potential for new antiviral drug discovery in this area of nucleoside research is promising.
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